Figure 22. Rankogram for Unadjusted Fixed-effects Bayesian MTC Results for Myocardial Infarction*.

Figure 22Rankogram for Unadjusted Fixed-effects Bayesian MTC Results for Myocardial Infarction*

b.i.d. = twice daily; MTC = mixed treatment comparison; q.d. = once daily.

*Safety on treatment for rivaroxaban. Mahaffey 201078 (AHA) reports ITT HR in ROCKET AF for MI as 0.91 (0.72–1.16)

From: 7.12, Specific Outcome Results

Cover of Safety, Effectiveness, and Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation
Safety, Effectiveness, and Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation [Internet].
Wells G, Coyle D, Cameron C, et al.
Copyright © 2012 Canadian Collaborative for Drug Safety, Effectiveness and Network Meta-Analysis.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.